Feb 15, 2021
MediSieve Expands Their Lab Space
The expansion enabled MediSieve to have full control over safety and equipment to meet the company's R&D needs
LONDON – February 15, 2021 – The beginning of the year has been full of exciting changes. To comply with government guidelines for Covid-19 measures and requirements for workspaces as well as to increase experimental capacity MediSieve expanded their Lab Space in February 2021.
The expansion enabled MediSieve to have full control over safety and equipment to meet the company's R&D needs. Previously MediSieve shared a laboratory with other companies in the White City Innovation Hub, which inevitably made R&D slower. By moving to a new fully equipped laboratory MediSieve hopes to not only keep the significant progress in research going but advance it futher.
MediSieve's CTO Cristina Blanco-Andujar commented that:
"The expansion of the lab space has improved our workflow hugely as we now have dedicated areas for different activities so everything can be very controlled. In addition, this new space represents our development over the last year and makes our progression feel really tangible. The team is very excited about the future."
Expanding the lab space is a first step towards further growth and product development of the company.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: